Pharmacoeconomics of migraine by unknown
Scientific journals
Pharmacoeconomics (http://ww.adis.com/journals/pec/index.html)
This “is the benchmark journal for peer reviewed, authoritative and
practical articles on the application of pharmacoeconomics, out-
comes research and quality of life assessment to optimum drug
therapy and health outcomes.”
European Journal of Health Economics (http://www.link.springer.
de/link/service/journals/10198/index.htm)
The growing demand for health economics, in terms of method-
ologies of pharmacoeconomics analyses, cost-benefit analyses,
cost-minimization analyses, resource utilization and revenue
enhancement has led Springer Verlag to create and support this
interesting new journal.





European Commission Medicines Project (EURO-Medicines)
(http://ww.euromedicines.org)
A directory (EURO-Medicines) of all medicines available in
European countries was recently created. Such directory can be of
help to estimate the impact of migraine therapy by analyzing data
about utilization and expenditures for pharmaceutical compounds
selectively indicated for the treatment of migraine. Full access to
the site is available upon request.
University of York, Health Economics and Health Care Profes-
sionals Certificate and Diploma Programmes by Distance
Learning (http://www.york.ac.uk/res/herc/distance.htm) 
This website, offered by the Department of Economics and Related
Studies of The University of York, is designed for those working in
the health-care sector who wish to gain an accredited online quali-
fication in health economics. The programme is provided and cer-
tified by the University of York (UK), and is the result of a collab-
oration between the Department of Economics and Related
Studies, the Centre of Health Economics and the York Health
Economics Consortium. These programmes are available to resi-
dents in UK and Europe. The two programmes (Certificate and
Diploma) are organized with the availability of module work-
books, a tutor support, and the use of a Web-based learning system.
The programme fees for both levels are reported.
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Pharmacoeconomics of migraine
Migraine is a clinical condition with an high prevalence rate and
with an important social impact; however wide variations in clinical
phenotypes of the disease – i.e. intensity, frequency, duration of the
attacks and related disability – make it difficult to estimate its real
burden. Recently, some patient and scientific associations launched
capillary informative media campaigns centered on migraine aware-
ness, which redirected to specialized medical structures a great per-
centage of migraine patients, particularly those suffering from low-
frequency migraine. These patients often before denied any struc-
tured medical approach and were therefore excluded from any over-
all in-depth analysis of human, social and economic costs caused by
their disease. That phenomenon undoubtedly produced better care of
migraine in whole population with a consequent spiraling cost for
migraine management. However, today the major goal of a modern
healthcare system is to achieve the greatest possible efficiency and
effectiveness by allocation of available resources.
Pharmacoeconomics is the science that analyzes the costs of drug
therapy to healthcare systems and society. The translation of such
information and research outcomes into daily medical practice is the
main mission and the critical point of a modern healthcare system.
The scarce availability of healthcare resources, when compared to
enormous, daily boosting healthcare needs, has to be conjugated and
thus distributed with the concepts of wisdom, fairness and efficiency.
The management of the majority of migraine cases is centered
today on the treatment of the single attack by using triptans or over-
the-counter analgesics. Thus, the total expenditure for the treatment
of migraine attacks cannot be exactly determined, because anal-
gesics are currently used for most painful disorders, including
migraine.
There are multiple sites in the Web providing exhaustive infor-
mation about this issue, from scientific organizations to scientific
journals, from data banks to institutional drug availability and uti-
lization sites, all focusing on pharmacoeconomics. The Web sites
closest to migraine management and care have been selected and
described in this report. 
Not-for-profit organizations
The International Society for Pharmacoeconomics and Outcomes
Research (ISPOR) (http://www.ispor.org)
This site reflects the activity of this non-profit organization (ISPOR)
whose mission is to facilitate the interchange of scientific knowl-
edge in pharmacoeconomics and patient health outcomes. Probably
this is the most organized and exhaustive Web site in this area.
The Institute of Health Economics (IHE) (http://www.ihe.ca)
IHE promotes the exchange of initiatives related to health outcomes
and health policies between research institutes, academia, govern-
ment and industry.
